Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival
Abstract Background Gastric cancer (GC) is a significant cancer-related cause of death worldwide. GC’s most used chemotherapeutic regimen is based on platinum drugs such as cisplatin (CDDP). However, CDDP chemoresistance reduces the survival rate of advanced GC. The immune C-C chemokine receptor typ...
Saved in:
Main Authors: | Bárbara Mora-Lagos, María Elena Reyes, Lorena Lobos-Gonzalez, Matías del Campo, Kurt Buchegger, Louise Zanella, Ismael Riquelme, Carmen Gloria Ili, Priscilla Brebi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Biological Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40659-024-00581-3 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessing the role of Chemokine (C–C motif) ligand 14 in AKI: a European consensus meeting
by: Jay L. Koyner, et al.
Published: (2024-12-01) -
CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms
by: Raanan Greenman, et al.
Published: (2025-01-01) -
CCL5 Induces a Sarcopenic-like Phenotype via the CCR5 Receptor
by: Francisco Aguirre, et al.
Published: (2025-01-01) -
CCL21-CCR7 blockade prevents neuroinflammation and degeneration in Parkinson’s disease models
by: Felipe Saceanu Leser, et al.
Published: (2025-02-01) -
Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab
by: Francine Foss, et al.
Published: (2025-12-01)